Samitivej International Children's Hospital expands, advancing pediatric healthcare amidst rising medical tourism from the Gulf
Backed by a two billion THB ($58.9 million USD) investment, the expansion strengthens Samitivej's commitment to becoming Asia-Pacific's Leading Pediatric Referral Hub, providing specialised care, innovative treatments, and seamless medical coordination.
The expansion comes as Thailand strengthens its position as a global healthcare destination, attracting patients from across Asia and the Middle East. According to Statista, Thailand's medical tourism industry was valued at 29 billion THB in 2023 (around $820 million USD), with an estimated 3.07 million international patients seeking specialized care. Families from the GCC - including Saudi Arabia, the UAE, Kuwait, Oman, and Qatar - continue to choose Thailand for comprehensive health check-ups, cardiology, oncology, and neonatal care, drawn by its internationally accredited hospitals and advanced medical expertise.
Revolutionising pediatric care with advanced treatments
Samitivej International Children's Hospital redefines pediatric excellence, offering cutting-edge treatments for complex and rare conditions, including:
Open-Heart Surgery to Minimally Invasive Catheterisation – Complete heart care from birth, ensuring advanced treatment and faster recovery.
Haploidentical Bone Marrow Transplant (BMT) to CAR-T Cell Therapy – Advanced treatments for blood disorders and cancer.
Comprehensive Pediatric and Newborn Surgery – Expertise in performing procedures from head to toe, led by specialized doctors.
Epilepsy Treatment with Medication to Vagus Nerve Stimulation (VNS) Implants – Solutions for drug-resistant epilepsy.
Advancing Pediatric Excellence with Cutting-Edge Facilities
The new eight-floor hospital features 111 beds, including 12 for critically ill children and 8 neonatal intensive care beds. It integrates Smart Hospital technology for efficiency and patient-centered care. Key features include:
Hybrid Operating Room: Precision-driven newborn and pediatric surgical procedures using biplane imaging technology.
World-Class Pediatric Specialties: Multidisciplinary teams treating complex and rare conditions.
Advanced Neonatal and Pediatric Intensive Care: Specialised care for premature infants under 500 grams.
Cutting-Edge Rehabilitation Center: Robotic-assisted gait training, Hybrid Assistive Limb (HAL) therapy, and Redcord NEURAC systems.
Comprehensive International Patient Services: Pre-arrival teleconsultations, aeromedical transport, multilingual care teams, follow-up appointments, and medical evacuation and repatriation.
Global partnerships and medical expertise
As part of its commitment to delivering world-class pediatric healthcare, Samitivej collaborates with Doernbecher Children's Hospital (OHSU, USA) to enhance care for critically ill children, newborns, and trauma patients. A partnership with Takatsuki General Hospital (Japan) ensures specialised neonatal and allergy treatments, providing access to the latest pediatric advancements.
Pioneering smart hospital innovations
Samitivej leads in digital healthcare, integrating technology to enhance efficiency and patient care. Innovations include:
Well Kidz App: Manages medical records, appointments, and remote consultations.
Smart ER & Smart Ambulance Services: Real-time monitoring ensures rapid emergency response.
Smart OPD & Smart IPD: AI-powered cost estimation, queue tracking, and seamless patient-medical team communication.
D-Discharge System: Streamlined hospital discharge for greater convenience.
Exceptional pediatric outcomes and achievements
Samitivej delivers outstanding results:
7,000+ critical pediatric cases treated annually
1,000+ newborn and pediatric surgeries performed, including minimally invasive procedures
92% one-year survival rate for bone marrow transplants, surpassing global benchmarks
400+ newborns with heart conditions successfully treated through surgical correction
Specialised care provided for premature infants with birth weights below 500 grams
98% trust rating from families
A commitment to a healthier future for every child
Dr Surangkana Techapaitoon, deputy CEO of Samitivej and BNH Hospitals and director of Samitivej International Children's Hospital, stated: "We want to see a healthier future for every child by integrating innovation, world-class expertise, and compassionate care. This facility strengthens our role as a leading pediatric referral hub, expanding access to specialised treatment and ensuring children everywhere receive the best care from infancy through adolescence."
For more details, please visit: https://smtvj.com/3F5dPKC
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Arabian Post
7 hours ago
- Arabian Post
MediLink Therapeutics Taps Major Banks for Hong Kong Float
MediLink Therapeutics Ltd. is preparing to launch an initial public offering in Hong Kong, having secured China International Capital Corp., JPMorgan Chase & Co. and Morgan Stanley as its lead advisers, according to people with knowledge of the matter. The move comes as the clinical-stage biotech firm seeks to capitalise on growing investor interest in advanced tumour-targeting therapies and consolidate its platform of antibody‑drug conjugates. Founded in 2020 and headquartered in Suzhou with R&D operations in Shanghai and Boston, MediLink has developed a proprietary ADC technology known as TMALIN®. The platform facilitates precise delivery of cytotoxic agents to tumour cells, with the intention of widening therapeutic windows for solid tumour treatments. Its pipeline includes programs that have advanced to clinical stages in both China and the United States, supported by a Series B financing round of approximately USD 70 million in 2022. MediLink's strategic engagement of three underwriters reflects heightened confidence in anchor investors and broader syndication. China International Capital Corp. brings deep roots in Chinese capital markets and extensive IPO experience in the biotech sector. JPMorgan and Morgan Stanley add global banking heft and access to international investors. ADVERTISEMENT CICC itself is emerging as a top-tier sponsor for Hong Kong listings. It led or co-led 19 IPOs for Chinese corporates last year, raising USD 3.84 billion, positioning it as a dominant force amid market revival. The engagement of internationally renowned banks alongside CICC is likely aimed at boosting MediLink's valuation and widening investor interest both locally and abroad. While IPO details remain confidential, analysts suggest MediLink could seek a valuation in the mid‑to‑high hundreds of millions of dollars. That would reflect both the advanced stage of its pipeline and prevailing market multiples for ADC developers. Comparable biotech flotations in Hong Kong and the U.S. have reflected growing appetite for oncology-focused platforms. Alongside listing ambitions, MediLink continues to advance its clinical and licensing goals. In March it unveiled preclinical data at the American Association for Cancer Research annual meeting; earlier in the year it received FDA clearance for its IND application for YL217, its lead candidate. YL201, another programme, received Breakthrough Therapy Designation in January for treatment of recurrent/metastatic nasopharyngeal carcinoma. The company has also pursued strategic licensing agreements with global pharmaceutical firms to expand development and commercialisation capabilities. A licensing deal under discussion ahead of the IPO is believed aimed at enhancing distribution reach while reinforcing MediLink's balance sheet. The IPO effort is part of a broader resurgence in biotech listings in Hong Kong, where authorities have eased regulations to attract innovation-driven offerings. CICC and other banks have ramped up support for ADC and gene therapy companies, signalling a turning point after a lull in listings. ADVERTISEMENT MediLink's choice of banks aligns with a wider trend: CICC has co-sponsored blockbuster floats including the forthcoming mega‑IPO of CATL, while banks like Goldman Sachs and Morgan Stanley have also participated. In this context, MediLink is positioning itself to tap both deep domestic networks and international capital. Stakeholder sentiment appears optimistic. MediLink's management team, comprised of co‑founders Tony Xue and Jiaqiang Cai alongside C‑suite leaders experienced in drug development and financial strategy, has overseen steady progress in its ADC pipeline and established global partnerships. Jason Li's appointment as CFO in 2023 reportedly strengthened the company's capital market readiness. Market observers highlight challenges ahead. ADC development remains capital-intensive, clinical risks high, and competition fierce among domestic and international peers. Success will hinge on late‑stage data and licensing traction. At the same time, geopolitical tensions and volatility in Hong Kong equity markets may affect investor sentiment. MediLink must also navigate post‑IPO obligations, including regulatory reporting and corporate governance under Hong Kong's Main Board requirements. Mitigating execution risk will be critical, underscoring the role of its chosen bankers in underwriting diligence and market support. Analysts describe the listing as a pivotal moment: it offers the backing to fund Phase II/III efforts while elevating MediLink's corporate profile. For banks, it reinforces Hong Kong's appeal as a biotech capital market when compared with established centres like Nasdaq. With its IPO process underway, MediLink now awaits market timing and regulatory clearances before formally filing a prospectus. The company is expected to continue advancing clinical data, strengthening licensing ties, and preparing investor materials aligned with regulatory requirements.
Arabian Post
04-06-2025
- Arabian Post
Global Investors Eye Bangkok's Rarest Luxury Wellness Penthouses at Award-Winning ROMM Convent
Multi-Award Winning Development Captures International Attention with 2-Star Fitwel Certification, Asia Pacific Property Awards, and PropertyGuru Excellence Recognition BANGKOK, THAILAND – Media OutReach Newswire – 4 June 2025 – Proud Real Estate has unveiled an extraordinary investment opportunity at ROMM Convent—Bangkok's premier wellness-integrated residence in the prestigious Sathorn-Silom CBD. The only two duplex sky penthouses available, representing the pinnacle of luxury wellness living in Southeast Asia, are now available to discerning global investors. ROMM CONVENT – Duplex Sky Penthouse These architectural masterpieces have captured international attention, with ROMM Convent receiving multiple prestigious accolades including Best Condo Development and Best Architectural Design at the Asia Pacific Property Awards, Best Wellness Residences Development from PropertyGuru, and a coveted 2-Star Fitwel Built Certification—a global standard in wellness design excellence. ADVERTISEMENT Investors are drawn by proven returns, with rental yields of 4–5.8% per annum and capital gains averaging 3–5.4% annually. Amid a climate of accelerating international demand, ROMM Convent stands out as both a secure asset and an aspirational lifestyle investment—offering exceptional value in one of Southeast Asia's fastest-growing real estate markets. Bangkok's Luxury Market: A Magnet for Global Capital Bangkok continues to command the interest of investors worldwide, with the luxury condominium segment outpacing regional peers and anticipated to achieve sustained annual growth of 3–5% through 2027. In 2024 alone, international buyers accounted for 39% of total sales value, with large-format residences over 150 sq.m. in prime central locations witnessing robust absorption. The Silom–Sathorn district is in the midst of a transformation, with over THB 600 billion in public and private investment projected through 2035. This surge of mega-projects is redefining the urban landscape, creating new opportunities for capital appreciation and rental demand—particularly as Bangkok's tourism sector continues its strong recovery. ROMM Convent: A Sanctuary for Global Citizens ADVERTISEMENT Strategically positioned for expatriates, professionals, digital nomads, and retirees, ROMM Convent offers unrivaled access to both tradition and modernity. Residents enjoy proximity to Bangkok's leading international schools—including St. Andrews Sathorn, Shrewsbury International, and King's College—as well as world-class medical centers such as BNH Hospital, MedPark, and King Chulalongkorn Memorial Hospital. With average rental rates of THB 800–1,200 per sq.m. per month, the area delivers healthy yields of 4–5.8% per year and robust capital gains of approximately 3–5.4% annually, underpinned by consistently high tenant demand. The Pinnacle of Wellness-Integrated Living The Duplex Sky Penthouses at ROMM Convent are a masterclass in architectural innovation and holistic well-being. Each residence spans 418.61–467.86 sq.m., offering house-like layouts with soaring 6.45-meter ceilings and panoramic skyline views, including Bangkok's most iconic landmarks. Private rooftop gardens create a tranquil green haven, seamlessly visible from both living and bedroom spaces. Exceptional Features Include: • Ultra-Exclusive Ownership: Only two duplex penthouses available. • House-Like Living: Two-story layout located in the heart of Bangkok's CBD • Skyline Views: Panoramic vistas in three directions, including iconic landmarks like MahaNakhon and One Bangkok • Private Rooftop Garden: A serene green escape visible from the main living and bedrooms • Signature Design Elements: Full-height glass, custom wellness detailing, and a serene rooftop retreat. • Gourmet Entertaining: Ice Jade kitchen island, Gorenje ORA ITO appliances, and a 46-bottle wine cellar. • Sophisticated Finishes: Engineered walnut floors, stone-clad kitchens, premium fixtures, and bespoke cabinetry. • Grand Proportions: Four bedrooms, five bathrooms, powder room, and a flexible multi-purpose space. Wellness Technology & Privileged Services: • 2-Star Fitwel Certified Wellness: Recognized global standards in health-optimized living. • 24/7 Health Butler Concierge: Personalized healthcare coordination and support. • Six Levels of Wellness Amenities: Thoughtfully curated for holistic mind-body well-being. • Smart Home Ecosystem: Advanced technology for air quality, energy efficiency, and comfort. • Exclusive Healthcare Partnerships: VVIP privileges with BNH Hospital and BeDee by BDMS. Unmatched Value in Bangkok's Central Business District Starting at just THB 290,000 per sq.m., ROMM Convent's Duplex Sky Penthouses represent one of the most compelling luxury investments in the Sathorn district—delivering exceptional value compared to global property capitals. Ownership is further enhanced by immediate access to VVIP medical privileges at BNH Hospital including special discounts and personalized care from Thailand's top-tier medical professionals—, ensuring both peace of mind and premier healthcare for residents and their families. See also BNM's Policy Rate Call Looms: Octa Broker Highlights Inflation, Exchange Rate and Trade Challenges Limited International Allocation: Secure Your Early Investor Advantage As foreign ownership quotas rapidly reach capacity, Proud Real Estate is pleased to offer the exclusive Early Investor Package (available until June 30, 2025). This limited-time opportunity includes bespoke layout customization and privileged access to tailored services—making now the optimal moment for international investors to secure their stake in one of Bangkok's most rarefied addresses. Invest in an Iconic Lifestyle at ROMM Convent – Where Wellness Meets Luxury Seize the opportunity to own one of the last two Duplex Sky Penthouses at ROMM Convent, where visionary design, holistic wellness, and world-class investment potential converge. Availability is strictly limited—act now to elevate your lifestyle and portfolio with Bangkok's most coveted luxury residence. For more information and personalized assistance, please visit Proud Real Estate or call +662-026-8999. Note: This press release contains forward-looking statements about market performance and investment returns. Actual results may vary. Investors should conduct their own due diligence before making investment decisions. Hashtag: #ProudRealestate #AllisWell #RommConvent #LuxuryWellnessResidences #CondoSathorn #CondoHighRise #Condo #Bangkok #CBD The issuer is solely responsible for the content of this announcement. PROUD REAL ESTATE PUBLIC COMPANY LIMITED Proud Real Estate is Thailand's leading luxury wellness-focused property developer, renowned for creating holistic living environments that seamlessly integrate health optimization, sustainability, and timeless design. With a portfolio of internationally awarded projects, Proud Real Estate consistently delivers above-market investment returns while setting new benchmarks in luxury and resident well-being. The company gained global recognition for the development of InterContinental Residences Hua Hin, one of only eight world-class branded residences under the InterContinental name—further solidifying Proud's reputation for excellence in luxury real estate.
Web Release
02-06-2025
- Web Release
PureHealth drives insurance business growth with Daman's entry into Property and Casualty insurance market
PureHealth, the largest hospital and health insurance group in the Middle East, today announced the strategic expansion of its insurance arm, Daman, marking its transformation from a health-focused provider into a comprehensive, multi-line insurer with entry into the high-growth Property and Casualty (P&C) segment. As part of this evolution, Daman will adopt a new legal name: The National Insurance Company – Daman, reflecting its broadened scope and strengthened position within the UAE's dynamic insurance landscape. The transition reflects Daman's broader mission to meet the evolving protection needs of individuals and businesses across the emirates by offering them a broader suite of insurance services. As the insurance arm of PureHealth and the UAE's leading health insurer, Daman's expansion into the P&C segment supports its vision to become a comprehensive insurance provider and aligns with the group's commitment to deliver holistic care and coverage throughout all stages of life. Shaista Asif, Group Chief Executive Officer of PureHealth, stated: 'Daman's evolution reflects PureHealth's broader strategy to create a fully integrated healthcare and insurance platform that drives better customer service and long-term value creation. Expanding into the Property and Casualty segment enhances portfolio diversification, supports risk management across sectors, and reinforces our commitment to shaping a future-ready ecosystem aligned with the UAE's economic and social development priorities.' H.E. Khaled Binshaiban Almheiri, Chairman of The National Insurance Company – Daman, commented: 'For nearly two decades, Daman has set the benchmark for health insurance in the UAE. This evolution marks a pivotal chapter – expanding our focus to offer a broader range of insurance solutions while maintaining the same rigour, trust and customer-first mindset our members know and value. By protecting individuals, businesses and assets, we are proud to play a central role in supporting the UAE's vision for sustainable wellbeing and long-term economic resilience.' Daman currently provides health coverage to more than three million members across a network of over 3,000 healthcare providers in the UAE. Backed by a resilient operational backbone, Daman brings together AI-powered underwriting, industry-leading efficiency in claim settlement, and a multilingual service delivery infrastructure to seamlessly support its expansion into new insurance verticals, without compromising its longstanding reputation for excellence. As per the Central Bank of the UAE (CBUAE), the total number of written insurance policies for all types of insurance within the UAE increased to 14.6 million policies year-on-year in 2023, compared to 8.4 million policies in 2022, due to a higher number of property and liability insurance policies. The UAE's P&C insurance market is poised for further accelerated growth, which is projected to reach nearly USD 16.8 billion by 2031, according to Verified Market Research. In response to this growing demand, the company will continue to operate under the well-established Daman brand, introducing new P&C products in phases while ensuring uninterrupted service for existing members. Daman was named the best perceived health insurance brand in the UAE, according to the UAE Healthcare 2024 report from Brand Finance – a recognition that reflects its commitment to excellence and mission to cultivate a healthier community. This strategic growth plan reinforces PureHealth's broader vision to advance the science of longevity and deliver the promise of holistic care, from prevention to protection, through a connected health and insurance ecosystem.
